Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs

Bone

Volumn 67, Issue , 2014, Pages 175-180

  Mazziotti, G ^a   Maffezzoni, F ^a   Doga, M ^a   Hofbauer, L C ^b   Adler, R A ^c   Giustina, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Glucocorticoids; Glucose metabolism; Osteocalcin; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; GLUCOSE; HEMOGLOBIN A1C; PARATHYROID HORMONE[1-34]; PREDNISONE; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BONE TURNOVER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; VERY ELDERLY; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; HOMEOSTASIS; METABOLISM; MIDDLE AGED; OSTEOPOROSIS;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; GLUCOCORTICOIDS; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE;

EID: 84904904756     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.008     Document Type: Article

References (36)

1. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
2. Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010, 123:877-884.
3. Mazziotti G., Gazzaruso C., Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011, 22:499-506.
4. van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39:81-93.
5. Clayton R.N., Raskauskiene D., Reulen R.C., Jones P.W. Mortality and morbidity in Cushing's disease over 50 years in stoke-on-trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011, 96:632-642.
6. Mazziotti G., Angeli A., Bilezikian J.P., Canalis E., Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006, 17:144-149.
7. Reid I.R., Chapman G.E., Fraser T.R., Davies A.D., Surus A.S., Meyer J., et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 1986, 62:379-383.
8. Prummel M.F., Wiersinga W.M., Lips P., Sanders G.T., Sauerwein H.P. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991, 72:382-386.
9. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
10. Fulzele K., Riddle R.C., DiGirolamo D.J., Cao X., Wan C., Chen D., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
11. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008, 105:5266-5270.
12. Ferron M., McKee M.D., Levine R.L., Ducy P., Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 2012, 50:568-575.
13. Brennan-Speranza T.C., Henneicke H., Gasparini S.J., Blankenstein K.I., Heinevetter U., Cogger V.C., et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest 2012, 122:4172-4189.
14. Ferris H.A., Kahn C.R. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest 2012, 122:3854-3857.
15. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94:45-49.
16. Furusyo N., Ihara T., Hayashi T., Ikezaki H., Toyoda K., Ogawa E., et al. The serum undercarboxylated osteocalcin level and the diet of a Japanese population: results from the Kyushu and Okinawa Population Study (KOPS). Endocrine 2013, 43:635-642.
17. Schafer A.L., Sellmeyer D.E., Schwartz A.V., Rosen C.J., Vittinghoff E., Palermo L., et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 2011, 96:E1982-E1989.
18. Schwartz A.V., Schafer A.L., Grey A., Vittinghoff E., Palermo L., Lui L.Y., et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res 2013, 28:1348-1354.
19. Anastasilakis A., Goulis D.G., Koukoulis G., Kita M., Slavakis A., Avramidis A. Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis. Exp Clin Endocrinol Diabetes 2007, 115:108-111.
20. Sealand R., Razavi C., Adler R.A. Diabetes mellitus and osteoporosis. Curr Diab Rep 2013, 13:411-418.
21. Adler R.A. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep 2010, 8:10-14.
22. Griffith J.F., Genant H.K. New advances in imaging osteoporosis and its complications. Endocrine 2012, 42:39-51.
23. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34:S62-S69.
24. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650.
25. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.
26. Kindblom J.M., Ohlsson C., Ljunggren O., Karlsson M.K., Tivesten A., Smith U., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009, 24:785-791.
27. Yeap B.B., Chubb S.A., Flicker L., McCaul K.A., Ebeling P.R., Beilby J.P., et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010, 163:265-272.
28. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 2009, 161:723-729.
29. Mazziotti G., Bilezikian J., Canalis E., Cocchi D., Giustina A. New understanding and treatments for osteoporosis. Endocrine 2012, 41:58-69.
30. Burt M.G., Roberts G.W., Aguilar-Loza N.R., Frith P., Stranks S.N. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011, 96:1789-1796.
31. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
32. Usdin T.B., Gruber C., Bonner T.I. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 1995, 270:15455-15458.
33. Williams K., Abanquah D., Joshi-Gokhale S., Otero A., Lin H., Guthalu N.K., et al. Systemic and acute administration of parathyroid hormone-related peptide (1-36) stimulates endogenous beta cell proliferation while preserving function in adult mice. Diabetologia 2011, 54:2867-2877.
34. Rubin M.R., Silverberg S.J. Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 2012, 42:231-233.
35. Mazziotti G., Gola M., Bianchi A., Porcelli T., Giampietro A., Cimino V., et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 2011, 40:102-108.
36. Torti C., Mazziotti G., Soldini P.A., Focà E., Maroldi R., Gotti D., et al. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 2012, 41:512-517.